Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Pancreatic neuroendocrine tumors: entering a new era.

Oberstein PE, Remotti H, Saif MW, Libutti SK.

JOP. 2012 Mar 10;13(2):169-73. Review.

2.

Update on novel therapies for pancreatic neuroendocrine tumors.

Oberstein PE, Saif MW.

JOP. 2012 Jul 10;13(4):372-5. doi: 10.6092/1590-8577/964.

4.

Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.

Thompson LA, Kim M, Wenger SD, O'Bryant CL.

Ann Pharmacother. 2012 Sep;46(9):1212-9. doi: 10.1345/aph.1R087. Epub 2012 Sep 4. Review.

PMID:
22947595
5.

Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors.

Oberstein PE, Saif MW.

JOP. 2012 Jul 10;13(4):368-71. doi: 10.6092/1590-8577/965.

6.

[Chemotherapy for GI and pancreatic NETs].

Doi T.

Gan To Kagaku Ryoho. 2013 Jul;40(7):838-42. Japanese.

PMID:
23863723
8.

Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.

Oberg K.

Curr Opin Oncol. 2012 Jul;24(4):433-40. doi: 10.1097/CCO.0b013e328353d7ba. Review.

PMID:
22510940
9.

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G.

Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S91-102. doi: 10.1517/14728222.2012.665880. Epub 2012 Feb 29. Review.

PMID:
22372544
10.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
11.

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.

Wiedenmann B, Pavel M, Kos-Kudla B.

Neuroendocrinology. 2011;94(3):177-90. doi: 10.1159/000329386. Epub 2011 Aug 31. Review.

12.

Novel agents in gastroenteropancreatic neuroendocrine tumors.

Stevenson R, Libutti SK, Saif MW.

JOP. 2013 Mar 10;14(2):152-4. doi: 10.6092/1590-8577/1470. Review.

13.

Role of everolimus in pancreatic neuroendocrine tumors.

Goldstein R, Meyer T.

Expert Rev Anticancer Ther. 2011 Nov;11(11):1653-65. doi: 10.1586/era.11.145. Epub 2011 Sep 20. Review.

PMID:
21932937
14.

Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.

Oberstein PE, Saif MW.

Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4.

15.

Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.

Faivre S, Sablin MP, Dreyer C, Raymond E.

Endocrinol Metab Clin North Am. 2010 Dec;39(4):811-26. doi: 10.1016/j.ecl.2010.09.006. Review.

PMID:
21095547
16.

Everolimus for the treatment of pancreatic neuroendocrine tumors.

Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.

Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Epub 2012 Aug 8. Review.

PMID:
22873789
17.

Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.

Phan AT.

Cancer Treat Rev. 2013 Feb;39(1):3-9. doi: 10.1016/j.ctrv.2012.02.010. Epub 2012 Mar 27. Review.

PMID:
22459199
18.

The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.

Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL.

Cancer Res. 2012 Nov 15;72(22):5683-91. doi: 10.1158/0008-5472.CAN-12-2102. Epub 2012 Sep 17.

19.

Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.

Peng L, Schwarz RE.

Curr Mol Med. 2013 Mar;13(3):333-9. Review.

PMID:
23331005
20.

Is there a role of radiotherapy in the management of pancreatic neuroendocrine tumors (PNET)?

Saif MW, Ng J, Chang B, Russo S.

JOP. 2012 Mar 10;13(2):174-6. Review.

Supplemental Content

Support Center